Progen initiates Phase III liver cancer study

April 2008
PharmaWatch: Biotechnology;Apr2008, Vol. 7 Issue 4, p5
Market Research Report
The article reports on the global Phase III study conducted by Progen Pharmaceuticals Ltd. regarding the efficacy and safety of PI-88, an adjuvant treatment for liver cancer. It was stated that the study, which is called Pathway, is double-blinded, placebo-controlled clinical trial that investigates PI-88's effectiveness in the post resection liver cancer setting. In addition, the study requires 600 patients from different countries.


Related Articles

  • PROGEN REPORTS ON PHASE 3 OF PI-88 FOR LIVER CANCER.  // Worldwide Biotech;Feb2008, Vol. 20 Issue 2, p1 

    The article reports that Progen Pharmaceuticals Ltd. has provided an update on clinical trial enrollment associated with its phase 3 hepatocellular carcinoma study. The trial has begun initiating sites and is now open for patient enrollment, through a thorough examination of available surgical...

  • Nonhormonal Systemic Therapy for Advanced Breast Cancer: Do the Math! Bedard, Philippe l.; Piccart-Gebhart, Martine J. // JNCI: Journal of the National Cancer Institute;12/17/2008, Vol. 100 Issue 24, p1745 

    The article focuses on the systemic therapy for advanced breast cancer. It states that the Early Breast Cancer Trialists' Collaborative Group's compilation of breast cancer management and clinical trials have paved way for the development of adjuvant treatments for cancer. However, advances in...

  • Progen Raising $61M To Fund Phase III Cancer Trials Of PI-88. Shrine, Jim // BioWorld Today;5/4/2007, Vol. 18 Issue 87, p1 

    The article reports that Progen Pharmaceuticals Ltd. has embarked into financing agreements that will produce about $61 million to fund its Phase III cancer trials. The company has signed an agreement with U.S. institutional and other investors to sell 6.9 million shares for $32.8 million. The...

  • Data Monitoring Committees in Practice. Kerr, David; McBride, Ruth; Shemanski, Lynn // Applied Clinical Trials;Mar2004, Vol. 13 Issue 3, p42 

    Provides information about data monitoring committees DMC) and clinical trials in the U.S. Role of DMC; Reference to the draft guidance published by the Food and Drug Administration for deciding the need of the DMC in clinical trials; Scenarios under which a DMC might recommend stopping a...

  • Clinical drug trials and the role of the nurse. Rath, Louise; Hitchcock, Alison; Oakley, Marion; Graham, Janet // Australian Nursing Journal;May2003, Vol. 10 Issue 10, p1CU 

    Presents an overview of how clinical drug trials are conducted in Australia. Phases of drug trials; Ethical considerations; Role of the research and clinical nurse in the trials. INSET: Common words associated with clinical drug trials.

  • Targeted Cancer Therapies Lagging. Hampton, Tracy // JAMA: Journal of the American Medical Association;10/25/2006, Vol. 296 Issue 16, p1951 

    The article states that the U.S. Food and Drug Administration has created a new program called the Critical Path Initiative to improve the preclinical and clinical testing of drugs and medical devices used in the molecular diagnosis and treatment of cancer. The initiative will use biomarkers to...

  • Neoadjuvant and adjuvant therapy for renal cell carcinoma: a new treatment paradigm for locally advanced and metastatic disease in the era of targeted therapy. Krieger, Laurence; Kristeleit, Hartmut; Chowdhury, Simon // Advances in Oncology;2010, Vol. 5 Issue 3, p10 

    The article discusses the relevance of neoadjuvant and adjuvant systematic therapies to renal cell carcinoma assessment. It enumerates several possible advantages of the neoadjuvant therapy including its responses in the primary tumour, the preservation of renal function in nephronsparing...

  • P-0114OUTCOMES OF COMBINED, CONCURRENT, AND SEQUENTIAL INTERVENTIONAL THERAPY FOR HUGE HEPATOCELLULAR CARCINOMA. An, Xiao; Wang, Jingbing; Li, Ke // Annals of Oncology;Jun2013, Vol. 24 Issue suppl_4, piv68 

    No abstract available.

  • Hepatic resection with or without adjuvant iodine-131-lipiodol for hepatocellular carcinoma: a comparative analysis. Chua, Terence; Saxena, Akshat; Chu, Francis; Butler, S.; Quinn, Richard; Glenn, Derek; Morris, David // International Journal of Clinical Oncology;Apr2011, Vol. 16 Issue 2, p125 

    Background: Resection of hepatocellular carcinoma (HCC) is potentially curative; however, recurrence is common. To date, few or no effective adjuvant therapies have been adequately investigated. This study evaluates the efficacy of adjuvant iodine-131-lipiodol after hepatic resection through the...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics